Completed PHASE1 INTERVENTIONAL 1-arm NCT00593463

Drug Discrimination in Methadone-Maintained Humans Study 1 (OMDD1)

Sponsor: University of Arkansas

Interventions Cycloserine Diltiazem Gabapentin Isradipine Naloxone Nifedipine Placebo Saline Verapamil

Updated 6 times since 2017 Last updated: Mar 10, 2011 Started: Sep 30, 2006 Primary completion: May 31, 2010 Completion: May 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Drug Dependence and is currently completed. University of Arkansas leads this study, which shows 6 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Sep 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Arkansas

Data source: University of Arkansas

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Little Rock, United States